Industry Overview

UK DNA Vaccine Market was valued at $52.06 million in 2025 and is projected to reach $81.62 million by 2035, growing at a CAGR of 4.7% during the forecast period (2026–2035).  The market is growing due to increasing adoption of DNA vaccines in both human and veterinary healthcare, driven by the need for rapid, scalable, and targeted immunization solutions. Advances in plasmid DNA vaccine technology have enhanced vaccine stability and efficacy, enabling the development of treatments for complex infectious diseases and oncology applications. Concurrently, improvements in plasmid DNA delivery methods have facilitated efficient cellular uptake and immune response, supporting broader clinical adoption. Regulatory encouragement and investment in innovative vaccine platforms have further accelerated research and commercialization efforts.

Market Dynamics

Rising Clinical Trials and Pipeline Expansion

The UK DNA vaccine market is witnessing a notable increase in clinical trial activity, reflecting intensified research into both human and animal DNA vaccines. Pharmaceutical and biotech companies are expanding their development pipelines to include vaccines targeting infectious diseases and oncology indications. Strategic collaborations with contract development and manufacturing organizations are enabling faster translation from preclinical research to early?phase human trials. This trend is further supported by government initiatives promoting innovative vaccine platforms and facilitating regulatory pathways. As a result, the UK market is experiencing heightened development momentum and diversified product offerings.

Integration of Advanced Plasmid Delivery Technologies

Advancements in plasmid DNA delivery systems are driving market growth in the UK by improving vaccine potency and patient response rates. Novel delivery approaches, including electroporation and nanoparticle-based methods, enhance cellular uptake and immunogenicity, enabling broader application across therapeutic areas. Companies are increasingly adopting these technologies to optimize clinical outcomes and support large-scale vaccine production. The adoption of sophisticated delivery platforms is also encouraging investment in next-generation DNA vaccines. Consequently, the market is becoming more competitive and technologically advanced, reinforcing the strategic role of DNA vaccines in healthcare innovation.

Market Segmentation

• Based on the type, the market is segmented into animal DNA vaccine, and human DNA vaccine.
• Based on the technology, the market is segmented into plasmid DNA vaccines technology, and plasmid DNA delivery technology.
• Based on the application, the market is segmented into oncology, infectious diseases, and others.

Human DNA Vaccine Sub-segment: Growth Driven by Infectious Disease Demand

The human DNA vaccine sub-segment is experiencing significant growth in the UK, primarily driven by the rising prevalence of infectious diseases and the need for rapid, targeted immunization strategies. Increased investment in clinical trials for vaccines against emerging viral infections has strengthened the development pipeline and accelerated regulatory approvals. The segment benefits from technological advances in plasmid DNA design that improve antigen expression and immune response. Collaboration between biotech firms and CDMOs has further enhanced manufacturing scalability for human DNA vaccines. Collectively, these factors are contributing to robust market expansion within the human DNA vaccine category.

Plasmid DNA Delivery Technology Sub-segment: Expansion Fueled by Advanced Delivery Innovations

The plasmid DNA delivery technology sub-segment is expanding in the UK due to innovations that enhance cellular uptake and immunogenicity, thereby improving vaccine efficacy. Emerging delivery platforms, including electroporation and nanoparticle-based systems, are facilitating clinical adoption across infectious disease and oncology applications. Companies are increasingly investing in these technologies to optimize therapeutic outcomes and support regulatory compliance for DNA vaccines. Integration of advanced delivery methods also allows efficient scale-up for commercial production, addressing growing demand. As a result, this sub-segment is becoming a critical driver of the overall DNA vaccine market in the UK.

Market Players Outlook

The major companies operating in the UK DNA vaccine market include 4basebio PLC, Charles River Laboratories International, Inc., Cobra Biologics Ltd, Scancell Holdings plc, Touchlight Ltd, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In January 2026, the FDA approved the IND application for Scancell Holdings' global phase 3 trial of iSCIB1+, a DNA plasmid vaccine for advanced melanoma, starting in 2026.
• In April 2025, 4basebio in Cambridge, UK, announced it received GMP certification from the MHRA. This license allows them to provide GMP-grade synthetic DNA for clinical programs in cell and gene therapy and vaccine development.
• In January 2025, Touchlight's Hampton UK facility received GMP certification, making it the first synthetic DNA manufacturer globally approved to produce Active Pharmaceutical Ingredients (API). This positions Touchlight uniquely to support customers in developing DNA vaccines and non-viral gene therapies.
• 4basebio PLC reported a significant revenue increase in 2024, doubling its DNA sales to reach £933,000. The company advanced its product supply for clinical trials, providing opDNA™ to HelixNano for an mRNA vaccine trial and GMP-grade synthetic DNA to a top pharmaceutical firm.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the UK DNA vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.